Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, safety and tolerability of ASP5354 in participants with renal impairment vs healthy volunteers
jRCT2031220304Phase 1Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2022
- Modality
- Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of pudexacianinium chloride in chronic kidney disease (CKD) (4 arms), sponsored by Astellas Pharma. Primary endpoints: Pharmacokinetics of ASP5354 in plasma and Pharmacokinetics of ASP5354 in urine. Started Sep 2022; status: completed.
02
Drugs
pudexacianinium chloride
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT2031220304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220304.